Literature DB >> 10862829

Effect of nepadutant at tachykinin NK(2) receptors in human intestine and urinary bladder.

R Patacchini1, S Giuliani, A Turini, G Navarra, C A Maggi.   

Abstract

We have characterized the action of the tachykinin NK(2) receptor antagonist nepadutant (c¿[(beta-D-GlcNAc)Asn-Asp-Trp-Phe-Dpr-Leu]c(2 beta-5 beta)¿) in the human isolated ileum, colon and urinary bladder. Nepadutant (30-1000 nM) competitively antagonized neurokinin A- or [beta Ala(8)]neurokinin A-(4-10)-induced contractions in all tissues, with pK(B)=8.3 (ileum and colon) and pK(B)=8.5 (bladder). In contrast, the nonpeptide tachykinin NK(2) receptor antagonist SR 48968 (or (S)-N-methyl-N [4-acetylamino-4-phenylpiperidino)-2-(3, 4-dichlorophenyl) butyl] benzamide) (30-1000 nM) produced insurmountable antagonism in all preparations. The tachykinin NK(2) receptor blockade produced by nepadutant in the colon was fully reversed by washout, whereas that produced by SR 48968 was not. Nepadutant (1 microM) greatly reduced (by 70-80%) the nonadrenergic noncholinergic (NANC) contractile off-response evoked by electrical field stimulation in the human ileum, and almost abolished it in the presence of the tachykinin NK(1) receptor antagonist GR 82334 (or: [[(S,S) Pro-Leu (spiro-gamma-lactam)](9,10),Trp(11)]Physalaemin (1-11)) (1 microM). The present results show that nepadutant is a potent, competitive and reversible antagonist at human tachykinin NK(2) receptors and provide further evidence that tachykinins act as excitatory NANC neurotransmitters in the human small intestine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862829     DOI: 10.1016/s0014-2999(00)00346-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Tachykinin NK1 and NK2 receptors mediate inhibitory vs excitatory motor responses in human isolated corpus cavernosum and spongiosum.

Authors:  Riccardo Patacchini; Guido Barbagli; Enzo Palminteri; Massimo Lazzeri; Damiano Turini; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa.

Authors:  Iain R Tough; Christine A Lewis; John Fozard; Helen M Cox
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-24       Impact factor: 3.000

Review 3.  Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome.

Authors:  Alessandro Lecci; Angela Capriati; Carlo Alberto Maggi
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.